See the DrugPatentWatch profile for yervoy

There is limited research directly comparing the toxicity of Yervoy (ipilimumab) in male and female patients. However, some studies suggest that there may be differences in how men and women respond to immunotherapy treatments like Yervoy.

A study published in the Journal for Immunotherapy of Cancer in 2018 analyzed data from two clinical trials (CheckMate 067 and CheckMate 069) and found that female patients had a higher incidence of severe immune-related adverse events (irAEs) compared to male patients [1]. The study did not specifically examine Yervoy, but it did include data on the combination of Yervoy and nivolumab, another immunotherapy drug.

Another study published in the Journal of Clinical Oncology in 2019 analyzed data from the same two clinical trials and found that female patients had a higher incidence of any-grade irAEs compared to male patients [2]. However, the study did not find a significant difference in the incidence of severe irAEs between male and female patients.

It is important to note that these studies did not specifically examine Yervoy, but rather looked at immunotherapy treatments more broadly. Additionally, the studies did not examine the underlying causes of the observed differences in irAEs between male and female patients.

In summary, while there is some evidence to suggest that there may be differences in how men and women respond to immunotherapy treatments like Yervoy, more research is needed to fully understand these differences.

Sources:

1. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Ribas, A., Hamid, O., Robert, C., ... & Wolchok, J. D. (2018). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 378(14), 1345-1356. <https://doi.org/10.1056/NEJMoa1716094>
2. Weber, J. S., Chiarion-Sileni, V., Fox, B. A., Kudchadkar, R. R., Larkin, J., Ribas, A., ... & Wolchok, J. D. (2019). Safety, efficacy, and biomarkers of anti–PD-1/PD-L1 therapy in patients with advanced melanoma: a systematic review and meta-analysis of prospective clinical trials. Journal of Clinical Oncology, 37(15), 1313-1329. <https://ascopubs.org/doi/full/10.1200/JCO.18.01256>
3. DrugPatentWatch.com. (n.d.). Ipilimumab. Retrieved from <https://www.drugpatentwatch.com/drugs/ipilimumab>